<DOC>
	<DOCNO>NCT02054897</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial investigate efficacy safety semaglutide once-weekly versus placebo drug-naïve subject type 2 diabetes . ( SUSTAIN™ 1-Monotherapy ) .</brief_summary>
	<brief_title>Efficacy Safety Semaglutide Once-weekly Versus Placebo Drug-naïve Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>For Japan : Male female , age equal 20 year time sign inform consent Subjects diagnose type 2 diabetes treat diet exercise least 30 day screen HbA1c 7.0 10.0 % ( 53 86 mmol/mol ) ( inclusive ) Female pregnant , breastfeed intend become pregnant childbearing potential use adequate contraceptive method ( adequate contraceptive measure require local regulation practice ) throughout trial include 5 week followup period . United Kingdom : Adequate contraceptive measure define establish use oral , injected implant hormonal method contraception , placement intrauterine device intrauterine system , barrier method contraception ( condom occlusive cap spermicidal foam/gel/film/cream/suppository ) , male sterilisation ( partner sole partner subject ) , true abstinence ( line prefer usual lifestyle ) Any chronic disorder severe disease , opinion investigator , might jeopardise subject 's safety compliance protocol Treatment glucose lower agent ( ) period 90 day prior screen . An exception shortterm treatment ( long 7 day total ) insulin connection intercurrent illness History chronic idiopathic acute pancreatitis Screening calcitonin value equal 50 ng/L ( pg/mL ) Personal family history medullary thyroid carcinoma multiple endocrine neoplasia syndrome type 2 ( MEN 2 ) Impaired renal function define eGFR ( estimate glomerular filtration rate ) 30 mL/min/1.73 m^2 per modification diet renal disease ( MDRD ) formula ( 4 variable version ) Acute coronary cerebrovascular event within 90 day randomisation Heart failure , New York Heart Association class IV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>